Medicare Part D coverage · 0.35 · RxCUI 1544390
0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]
Per the CMS 2026 Part D formulary file, 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] is covered by 302 Medicare Part D plans (6% of enrollable products), averaging Tier 3.1, with prior authorization required on 3.2% of covering formularies.
- 6%
- Plan coverage
- 302
- Plans covering
- T3.1
- Avg tier
- 3.2%
- Prior auth required
What the CMS Formulary Data Shows for 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]
Per the CMS 2026 Part D formulary file, 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] (RxNorm concept RXCUI 1544390, generic name 0.35) appears on 62 distinct formulary files spanning 302 Medicare Part D plan offerings - 6% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 3.1.
Real-world access to 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] depends on utilization management as much as tier placement: 3.2% of covering formularies require prior authorization. 80.6% require step therapy. 3.2% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 5,262 Part D beneficiaries filled 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] in 2023, with total plan-and-beneficiary spending of $20,891,563 and an average per-beneficiary annual cost of $3,970.27. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] today.
Coverage Details
- Formularies covering
- 62
- Plans covering
- 302
- Coverage rate
- 6%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 3.2% of formularies
- Step therapy required
- 80.6% of formularies
- Quantity limits
- 3.2% of formularies
2023 Medicare Spending
- Beneficiaries
- 5,262
- Total spending
- $20,891,563
- Avg per beneficiary
- $3,970.27
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]
100 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Elevate Medicare Choice (HMO D-SNP) | Denver Health Medical Plan, Inc. | T1 | No | $0 | CO |
| AllCare Advantage Redwood Rx (HMO D-SNP) | Allcare Health Plan, Inc. | T1 | No | $0 | OR |
| PrimeWest Senior Health Complete (HMO D-SNP) | Primewest Rural MN Health Care Access Initiative | T1 | No | $0 | MN |
| Prime Health Complete (HMO D-SNP) | Primewest Rural MN Health Care Access Initiative | T1 | No | $0 | MN |
| Alterwood Advantage Dual Secure (HMO D-SNP) | Alterwood Advantage, Inc. | T1 | No | $0 | MD |
| Nascentia Dual Advantage (HMO D-SNP) | Visiting Nurse Association OF Central NEW York | T1 | No | $0 | NY |
| Abilis Health Community (HMO I-SNP) | Signature Advantage, LLC | T1 | No | $0 | KY, TN |
| Arkansas Integrated Providers (AIP) Dual Advantage (HMO D-SNP) | Arkansas Superior Select, Inc. | T1 | No | $0 | AR |
| Mass General Brigham SCO (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | No | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | Mass General Brigham Health Plan, Inc | T1 | No | $0 | MA |
| Gold Dialysis & Kidney Complete (HMO-POS C-SNP) | Gold Kidney OF Florida Inc | T1 | No | $4.80 | FL |
| Texas Independence Health Plan, Inc. (HMO I-SNP) | Texas Independence Health Plan, Inc. | T1 | No | $4.80 | TX |
| Texas Independence Community Plan (HMO I-SNP) | Texas Independence Health Plan, Inc. | T1 | No | $4.80 | TX |
| Tribute Select (HMO-POS I-SNP) | Arkansas Superior Select, Inc. | T1 | No | $8.90 | AR |
| ATRIO Special Needs Plan (HMO D-SNP) | Atrio Health Plans | T1 | No | $10.50 | OR |
| ATRIO Special Needs Plan (HMO D-SNP) | Atrio Health Plans | T1 | No | $10.50 | OR |
| Gold Dialysis & Kidney Complete (HMO-POS C-SNP) | Gold Kidney OF Arizona | T1 | No | $17.00 | AZ |
| Alterwood Advantage Dual Value (HMO D-SNP) | Alterwood Advantage, Inc. | T1 | No | $31.20 | MD |
| Valor Health Plan (HMO I-SNP) | TSG Guard, Inc. | T1 | No | $31.40 | OH |
| WV Senior Advantage (HMO I-SNP) | West Virginia Senior Advantage, Inc. | T1 | No | $32.70 | WV |
Show the next 30 plans
Showing top 50 of 100 plans.
Frequently Asked Questions
Is 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] covered by Medicare Part D?
Yes, 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] is covered by 302 Medicare Part D plans (6% of all Part D formularies).
What tier is 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] on Medicare Part D plans?
0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] averages Tier 3.1 across Part D plans, ranging from Tier 1 to Tier 4.
Does 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] require prior authorization?
3.2% of Part D formularies require prior authorization for 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]. Step therapy: 80.6%. Quantity limits: 3.2%.
How much does Medicare spend on 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo]?
In 2023, total Medicare Part D spending on 0.35 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] was $20,891,563, covering 5,262 beneficiaries. The average spend per beneficiary was $3,970.27.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- sevelamer hydrochloride 400 MG Oral Tablet 3.2% PA
- acetaminophen 325 MG / hydrocodone bitartrate 2.5 MG Oral Tablet 3.2% PA
- 84 HR estradiol 0.00104 MG/HR Transdermal System [Dotti] 3.2% PA
- 50/50 Release 24 HR methylphenidate hydrochloride 60 MG Extended Release Oral Capsule 3.2% PA
- penciclovir 10 MG/ML Topical Cream 3.2% PA
- 0.3 ML methotrexate 50 MG/ML Auto-Injector [Rasuvo] 3.2% PA